Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)

被引：1
|
作者：
Bansback, N
Brennan, A
Sengupta, N
机构：
[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62129-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [31] Cost effectiveness of Adalimumab (HUMIRA®) plus Methotrexate vs. Etanercept (ENBREL) plus methotrexate in moderate to severe rheumatoid arthritis (RA)
    Davies, AS
    Hutton, J
    Weisman, MH
    Cifaldi, MA
    Pang, F
    Spencer-Green, GT
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 68 - 68
  • [32] Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    Bansback, NJ
    Brennan, A
    Ghatnekar, O
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 995 - 1002
  • [33] Humira - Adalimumab - Abbott Laboratories - New treatment for rheumatoid arthritis
    不详
    FORMULARY, 2003, 38 (02) : 78 - 79
  • [34] Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients.
    Krieckaert, Charlotte L. M.
    Nair, Sandhya C.
    Nurmohamed, M. T.
    van Dongen, Carlo J. J.
    Lems, Willem F.
    Lafeber, Floris P. J. G.
    Bijlsma, J. W. J.
    Wolbink, Gertjan
    Welsing, Paco M. J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S779 - S779
  • [35] COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB BIOSIMILAR COMPARED TO DELAYED BIOLOGIC TREATMENT INITIATION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY
    Porter, J.
    Stuart, P.
    Bartsch, R.
    Lebioda, A.
    VALUE IN HEALTH, 2021, 24 : S15 - S15
  • [36] EVALUATING THE COST-EFFECTIVENESS OF PERSONALIZED TREATMENT WITH ADALIMUMAB USING SERUM DRUG LEVEL AND ANTI-ADALIMUMAB ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS
    Krieckaert, C.
    Nair, S. C.
    Nurmohamed, M. T.
    van Dongen, C. J.
    Lems, W. F.
    Lafeber, F. P.
    Bijlsma, J. W.
    Wolbink, G.
    Welsing, P. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 104 - 104
  • [37] Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
    Metghalchi, Yalda
    Yaghoubi, Neda
    Yousefi, Nazila
    Ahmadi, Razieh
    Kargar, Alireza
    Zargaran, Marzieh
    Rezaei, Soheila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2024, 22 (01):
  • [38] A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    Chen, Y-F
    Jobanputra, P.
    Barton, P.
    Jowett, S.
    Bryan, S.
    Clark, W.
    Fry-Smith, A.
    Burls, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) : 1 - +
  • [39] Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life
    Benucci, Maurizio
    Saviola, Gianantonio
    Baiardi, Paola
    Manfredi, Mariangela
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (11) : 1465 - 1469
  • [40] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
12345